Breaking News

Dr. Reddy's Expands CPS Business

October 8, 2012

Enables cGMP manufacture of PEGtech range at commercial scale

The Custom Pharmaceutical Services (CPS) business of Dr. Reddy’s Laboratories has expanded operations at its facility in Mirfield, UK in the areas of activated mPEG manufacturing and the development and manufacture of NCE APIs for preclinical through to commercial development.
The expansion enables the manufacture of its PEGtech range at commercial metric ton scale quantities in a cGMP environment. Dr. Reddy’s has eight API manufacturing facilities, six FDA-approved plants in India, one FDA-approved plant in Mexico, and one FDA-approved plant in Mirfield, UK.
Dr. R. Ananthanarayanan, president of the Pharmaceutical Services and Active Ingredients business of Dr. Reddy’s said, “This expansion builds on our commitment to expand operations in UK and provide a superior network of cGMP manufacturing to support our global customer base. PEGylation is one area where we felt the need for expanding our capabilities. We have invested in multiple technology areas and the expansion will add significant value in the areas of mPEGs and cGMP API manufacturing.”

Related Contract Manufacturing:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks